The potential therapeutic role of statins in central nervous system autoimmune disorders

O. Stüve, S. Youssef, S. Dunn, A. J. Slavin, L. Steinman, S. S. Zamvil

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

3-Hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 'statins' are widely used oral cholesterol-lowering drugs. Statins competitively inhibit HMG-CoA reductase, the enzyme that catalyzes conversion of HMG-CoA to L-mevalonate, a key intermediate in cholesterol synthesis. Certain metabolites of mevalonate are also involved in posttranslational modification of specific proteins involved in cell proliferation and differentiation. Thus, statins have important biologic effects that may be independent of their cholesterol-reducing properties. Recent studies indicate that statins have antiinflammatory and neuroprotective properties which may be beneficial in the treatment of multiple sclerosis as well as other central nervous system (CNS) neurodegenerative diseases. This article will outline current experimental evidence that may suggest potential clinical benefits for patients with CNS autoimmune disorders. Ultimately, clinical trials will have to determine the safety and efficacy of statins in this patient population.

Original languageEnglish (US)
Pages (from-to)2483-2491
Number of pages9
JournalCellular and Molecular Life Sciences
Volume60
Issue number11
DOIs
StatePublished - Nov 2003

Fingerprint

Autoimmune Diseases of the Nervous System
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Central Nervous System Diseases
Neurology
Coenzyme A
Mevalonic Acid
Cholesterol
Oxidoreductases
Neurodegenerative diseases
Therapeutics
Cell proliferation
Post Translational Protein Processing
Metabolites
Neurodegenerative Diseases
Multiple Sclerosis
Cell Differentiation
Anti-Inflammatory Agents
Cell Proliferation
Clinical Trials
Safety

Keywords

  • Experimental autoimmune encephalomyelitis
  • HMG CoA reductase inhibitors
  • Multiple sclerosis
  • Statins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Cell Biology

Cite this

The potential therapeutic role of statins in central nervous system autoimmune disorders. / Stüve, O.; Youssef, S.; Dunn, S.; Slavin, A. J.; Steinman, L.; Zamvil, S. S.

In: Cellular and Molecular Life Sciences, Vol. 60, No. 11, 11.2003, p. 2483-2491.

Research output: Contribution to journalArticle

Stüve, O. ; Youssef, S. ; Dunn, S. ; Slavin, A. J. ; Steinman, L. ; Zamvil, S. S. / The potential therapeutic role of statins in central nervous system autoimmune disorders. In: Cellular and Molecular Life Sciences. 2003 ; Vol. 60, No. 11. pp. 2483-2491.
@article{1095db5e26f84150ae8f5253c4507046,
title = "The potential therapeutic role of statins in central nervous system autoimmune disorders",
abstract = "3-Hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 'statins' are widely used oral cholesterol-lowering drugs. Statins competitively inhibit HMG-CoA reductase, the enzyme that catalyzes conversion of HMG-CoA to L-mevalonate, a key intermediate in cholesterol synthesis. Certain metabolites of mevalonate are also involved in posttranslational modification of specific proteins involved in cell proliferation and differentiation. Thus, statins have important biologic effects that may be independent of their cholesterol-reducing properties. Recent studies indicate that statins have antiinflammatory and neuroprotective properties which may be beneficial in the treatment of multiple sclerosis as well as other central nervous system (CNS) neurodegenerative diseases. This article will outline current experimental evidence that may suggest potential clinical benefits for patients with CNS autoimmune disorders. Ultimately, clinical trials will have to determine the safety and efficacy of statins in this patient population.",
keywords = "Experimental autoimmune encephalomyelitis, HMG CoA reductase inhibitors, Multiple sclerosis, Statins",
author = "O. St{\"u}ve and S. Youssef and S. Dunn and Slavin, {A. J.} and L. Steinman and Zamvil, {S. S.}",
year = "2003",
month = "11",
doi = "10.1007/s00018-003-3146-0",
language = "English (US)",
volume = "60",
pages = "2483--2491",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "11",

}

TY - JOUR

T1 - The potential therapeutic role of statins in central nervous system autoimmune disorders

AU - Stüve, O.

AU - Youssef, S.

AU - Dunn, S.

AU - Slavin, A. J.

AU - Steinman, L.

AU - Zamvil, S. S.

PY - 2003/11

Y1 - 2003/11

N2 - 3-Hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 'statins' are widely used oral cholesterol-lowering drugs. Statins competitively inhibit HMG-CoA reductase, the enzyme that catalyzes conversion of HMG-CoA to L-mevalonate, a key intermediate in cholesterol synthesis. Certain metabolites of mevalonate are also involved in posttranslational modification of specific proteins involved in cell proliferation and differentiation. Thus, statins have important biologic effects that may be independent of their cholesterol-reducing properties. Recent studies indicate that statins have antiinflammatory and neuroprotective properties which may be beneficial in the treatment of multiple sclerosis as well as other central nervous system (CNS) neurodegenerative diseases. This article will outline current experimental evidence that may suggest potential clinical benefits for patients with CNS autoimmune disorders. Ultimately, clinical trials will have to determine the safety and efficacy of statins in this patient population.

AB - 3-Hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 'statins' are widely used oral cholesterol-lowering drugs. Statins competitively inhibit HMG-CoA reductase, the enzyme that catalyzes conversion of HMG-CoA to L-mevalonate, a key intermediate in cholesterol synthesis. Certain metabolites of mevalonate are also involved in posttranslational modification of specific proteins involved in cell proliferation and differentiation. Thus, statins have important biologic effects that may be independent of their cholesterol-reducing properties. Recent studies indicate that statins have antiinflammatory and neuroprotective properties which may be beneficial in the treatment of multiple sclerosis as well as other central nervous system (CNS) neurodegenerative diseases. This article will outline current experimental evidence that may suggest potential clinical benefits for patients with CNS autoimmune disorders. Ultimately, clinical trials will have to determine the safety and efficacy of statins in this patient population.

KW - Experimental autoimmune encephalomyelitis

KW - HMG CoA reductase inhibitors

KW - Multiple sclerosis

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=20244386190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244386190&partnerID=8YFLogxK

U2 - 10.1007/s00018-003-3146-0

DO - 10.1007/s00018-003-3146-0

M3 - Article

C2 - 14625690

AN - SCOPUS:20244386190

VL - 60

SP - 2483

EP - 2491

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 11

ER -